ZA200309384B - New compounds useful in reflux disease. - Google Patents
New compounds useful in reflux disease. Download PDFInfo
- Publication number
- ZA200309384B ZA200309384B ZA200309384A ZA200309384A ZA200309384B ZA 200309384 B ZA200309384 B ZA 200309384B ZA 200309384 A ZA200309384 A ZA 200309384A ZA 200309384 A ZA200309384 A ZA 200309384A ZA 200309384 B ZA200309384 B ZA 200309384B
- Authority
- ZA
- South Africa
- Prior art keywords
- represents hydrogen
- formula
- compound according
- pharmaceutically acceptable
- benzothiazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 95
- 238000010992 reflux Methods 0.000 title claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 6
- 201000010099 disease Diseases 0.000 title claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 210000005070 sphincter Anatomy 0.000 claims description 7
- DUILGEYLVHGSEE-SSDOTTSWSA-N 2-[[(2r)-oxiran-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@@H]1CO1 DUILGEYLVHGSEE-SSDOTTSWSA-N 0.000 claims description 6
- 206010047700 Vomiting Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 230000001052 transient effect Effects 0.000 claims description 6
- NVIJJMLZIGNFCD-GSVOUGTGSA-N (2r)-3-amino-2-hydroxypropane-1-sulfinic acid Chemical compound NC[C@@H](O)CS(O)=O NVIJJMLZIGNFCD-GSVOUGTGSA-N 0.000 claims description 5
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 5
- 206010011224 Cough Diseases 0.000 claims description 5
- 206010015137 Eructation Diseases 0.000 claims description 5
- 208000031361 Hiccup Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 206010067171 Regurgitation Diseases 0.000 claims description 5
- 208000027687 belching Diseases 0.000 claims description 5
- 201000006145 cocaine dependence Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010013663 drug dependence Diseases 0.000 claims description 5
- 201000006549 dyspepsia Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000020341 sensory perception of pain Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- UYRCSPJNAZWIEB-GSVOUGTGSA-N (2r)-3-amino-2-fluoropropane-1-sulfinic acid Chemical compound NC[C@@H](F)CS(O)=O UYRCSPJNAZWIEB-GSVOUGTGSA-N 0.000 claims description 4
- OFASCSDWIZOXNM-LLVKDONJSA-N 2-[(2r)-3-(1,3-benzothiazol-2-ylsulfanyl)-2-hydroxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@@H](O)CSC1=NC2=CC=CC=C2S1 OFASCSDWIZOXNM-LLVKDONJSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- DUILGEYLVHGSEE-ZETCQYMHSA-N 2-[[(2s)-oxiran-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@H]1CO1 DUILGEYLVHGSEE-ZETCQYMHSA-N 0.000 claims description 3
- 206010020651 Hyperkinesia Diseases 0.000 claims description 3
- 208000000269 Hyperkinesis Diseases 0.000 claims description 3
- 206010057852 Nicotine dependence Diseases 0.000 claims description 3
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 3
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- CCRFCEFBBDHXRU-SNVBAGLBSA-N tert-butyl n-[(2r)-3-(1,3-benzothiazol-2-ylsulfanyl)-2-hydroxypropyl]carbamate Chemical compound C1=CC=C2SC(SC[C@H](O)CNC(=O)OC(C)(C)C)=NC2=C1 CCRFCEFBBDHXRU-SNVBAGLBSA-N 0.000 claims description 3
- UYRCSPJNAZWIEB-UHFFFAOYSA-N 3-amino-2-fluoropropane-1-sulfinic acid Chemical compound NCC(F)CS(O)=O UYRCSPJNAZWIEB-UHFFFAOYSA-N 0.000 claims description 2
- NZNDPBWNSJEMSJ-UHFFFAOYSA-N 3-amino-2-oxopropane-1-sulfinic acid Chemical compound NCC(=O)CS(O)=O NZNDPBWNSJEMSJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 4
- OFASCSDWIZOXNM-NSHDSACASA-N 2-[(2s)-3-(1,3-benzothiazol-2-ylsulfanyl)-2-hydroxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@H](O)CSC1=NC2=CC=CC=C2S1 OFASCSDWIZOXNM-NSHDSACASA-N 0.000 claims 1
- YCDWNZGUODQFGU-UHFFFAOYSA-N 2-hydroxypropyl carbamate Chemical compound CC(O)COC(N)=O YCDWNZGUODQFGU-UHFFFAOYSA-N 0.000 claims 1
- NVIJJMLZIGNFCD-UHFFFAOYSA-N 3-amino-2-hydroxypropane-1-sulfinic acid Chemical compound NCC(O)CS(O)=O NVIJJMLZIGNFCD-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- -1 hydroxy, mercapto Chemical class 0.000 description 27
- 239000007787 solid Substances 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 230000003301 hydrolyzing effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 9
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 125000005309 thioalkoxy group Chemical group 0.000 description 8
- 238000007126 N-alkylation reaction Methods 0.000 description 7
- 238000006698 hydrazinolysis reaction Methods 0.000 description 7
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000018 receptor agonist Substances 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229940054266 2-mercaptobenzothiazole Drugs 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000003158 myorelaxant agent Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229960000794 baclofen Drugs 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- NQIQHEDRCIERKN-SNVBAGLBSA-N tert-butyl n-[(2r)-3-(1,3-benzothiazol-2-ylsulfonyl)-2-hydroxypropyl]carbamate Chemical compound C1=CC=C2SC(S(=O)(=O)C[C@H](O)CNC(=O)OC(C)(C)C)=NC2=C1 NQIQHEDRCIERKN-SNVBAGLBSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KRVDMABBKYMBHG-UHFFFAOYSA-N Isoguvacine Chemical compound OC(=O)C1=CCNCC1 KRVDMABBKYMBHG-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- NHVRIDDXGZPJTJ-UHFFFAOYSA-N skf-97,541 Chemical compound CP(O)(=O)CCCN NHVRIDDXGZPJTJ-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 210000002182 synaptic membrane Anatomy 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 1
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 1
- CDRFJCGEQFWNFZ-UHFFFAOYSA-N 3-aminobutane-1-sulfinic acid 3-(benzylamino)propane-1-sulfinic acid 3-(methylamino)propane-1-sulfinic acid Chemical compound C(C1=CC=CC=C1)NCCCS(=O)O.CNCCCS(=O)O.NC(CCS(=O)O)C CDRFJCGEQFWNFZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NPGXQDBNBFXJKB-UHFFFAOYSA-N 3-azaniumylpropane-1-sulfinate Chemical compound NCCCS(O)=O NPGXQDBNBFXJKB-UHFFFAOYSA-N 0.000 description 1
- RNSIJRUPQJHCBR-UHFFFAOYSA-N 4-amino-3-(2-chlorophenyl)butanoic acid Chemical compound OC(=O)CC(CN)C1=CC=CC=C1Cl RNSIJRUPQJHCBR-UHFFFAOYSA-N 0.000 description 1
- QVFCDBKVVWSANR-UHFFFAOYSA-N 4-aminobutane-2-sulfinic acid Chemical compound OS(=O)C(C)CCN QVFCDBKVVWSANR-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CWXCLMVCKQHPGP-UHFFFAOYSA-N C1(=CC=CC=C1)CCNCCCS(=O)O.ClC1=CC=C(C=C1)CNCCCS(=O)O.NCC(CS(=O)O)O Chemical compound C1(=CC=CC=C1)CCNCCCS(=O)O.ClC1=CC=C(C=C1)CNCCCS(=O)O.NCC(CS(=O)O)O CWXCLMVCKQHPGP-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical compound OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- ZTHNRNOOZGJLRR-UHFFFAOYSA-N chembl112203 Chemical class NCCCP(O)=O ZTHNRNOOZGJLRR-UHFFFAOYSA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- ARSWIHOOXSOUMV-UHFFFAOYSA-N hydroxysulfanylformic acid Chemical compound OSC(O)=O ARSWIHOOXSOUMV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000016752 upper digestive tract disease Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
NEW COMPOUNDS USEFUL IN REFLUX DISEASE
The present invention is related to novel compounds useful in therapy, especially for the inhibition of transient lower oesophageal sphincter relaxations and for the treatment of gastro-oesophageal reflux disease (GORD), as well as to their pharmaceutically acceptable salts, solvates and stereoisomers. The invention is also related to processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.
Reflux
Gastro-oesophageal reflux disease (GORD) is the most prevalent upper gastrointestinal tract disease. Current therapy has aimed at reducing gastric acid secretion, or at reducing oesophageal acid exposure by enhancing oesophageal clearance, lower oesophageal sphincter tone and gastric emptying. The major mechanism behind reflux has earlier been considered to depend on a hypotonic lower oesophageal sphincter. However recent research (e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, 517-535) has shown that most reflux episodes occur during transient lower oesophageal sphincter relaxations, hereinafter referred to as TLOSR, i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GORD. 2s Consequently, there is a need for compounds which reduce the incidence of TLOSR and thereby prevent reflux.
Pharmaceutical compositions comprising a local anaesthetic, adapted to inhibit relaxation . of the lower oesophageal sphicter are disclosed in WO 87/04077 and in US 5,036,057.
Recently GABAg-receptor agonists have been shown to inhibit TLOSR which is disclosed in WO 98/11885.
GABAg receptor agonists
GABA (4-aminobutanoic acid) is an endogenous neurotransmitter in the central and peripheral nervous systems. Receptors for GABA have traditionally been divided into '
GABA, and GABAg receptor subtypes. GAB Ag receptors belong to the superfamily of G- protein coupled receptors. GAB Ag receptor agonists are being described as being of use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome (IBS) and as prokinetic and anti-tussive agents. GABAg receptor agonists have also been disclosed as useful in the treatment of emesis (WO 96/11680) and recently, as mentioned above, in the inhibition of TLOSR (WO 98/11885).
The most studied GABAg receptor agonist is baclofen (4-amino-3-(chlorophenyl)butanoic acid) disclosed in the Swiss patent No. CH 449, 046. Baclofen has for several years been 1s used as an antispastic agent. EP 0356128 A2 describes the use of the specific compound (3-aminopropyl)methylphosphinic acid, as a potent GAB Ag receptor agonist, in therapy.
EP 0181833 Al discloses substituted 3-aminopropylphosphinic acids which are found to have very high affinities towards GABAg receptor sites. In analogy to baclofen, the compounds can be used as for instance muscle relaxants. EP 0399949 Al discloses derivatives of (3-aminopropyl)methylphosphinic acid which are described as potent
GAB Ag receptor agonists. These compounds are stated to be useful as muscle relaxants.
EP 0463969 Al and FR 2722192 Al are both applications related to 4-aminobutanoic acid derivatives having different heterocyclic substituents at the 3-carbon of the butyl chain.
Structure-activity relationships of several phosphinic acid analogues with respect to their affinities to the GABAg receptor as well as their muscle relaxant effect are discussed in J.
Med. Chem. (1995), 38, 3297-3312.
Structure-activity relationships of several phosphinic acid analogues with respect to their affinities to the GAB Ag receptor as well as their muscle relaxant effect are discussed in J. | :
Med. Chem. (1995), 38, 3297-3312. In addition, some sulphinic acid analogues and their
GABAgp receptor activities are disclosed in Bioorg. & Med.Chem. Lett. (1998), 8, 3059-
) Outline of the invention ‘ The present invention provides novel compounds of the formula I
H BR. OH
NN (1)
Rs: R, ‘wherein R; represents hydrogen, hydroxy, C;-C7 alkyl, C1-C7 alkoxy or halogen;
R; represents hydrogen, hydroxy, mercapto, halogen, or an oxo group;
R; represents hydrogen or C1-C7 alkyl (optionally substituted with hydroxy, mercapto, C-
C7 alkoxy, C;-C7 thioalkoxy, aryl or heteroaryl), aryl or heteroaryl;
R, represents hydrogen, C1-C7 alkyl (optionally substituted with aryl or heteroaryl), aryl or heteroaryl; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, with the exceptions of: : oo. (3-aminopropyl)sulphinic acid; ) 25 - the racemate of (3-amino-1-methylpropyl)sulphinic acid - the racemate of (3-amino-3-methylpropyl)sulphinic acid - (N-methyl-3-aminopropyl)sulphinic acid - (N-benzyl-3-aminopropyl)sulphinic acid
- the racemate of (3-amino-2-hydroxypropyl)sulphinic acid - (N-(4-chlorophenylmethyl)-3-aminopropyl)sulphinic acid - (N-(2-phenylethyl)-3-aminopropyl)sulphinic acid 5s According to one embodiment of the invention the novel compound is selected from the group consisting of (3-amino-2-fluoropropyl)sulphinic acid, (25)-(3-amino-2- fluoropropyl)sulphinic acid, (2R)-(3-amino-2-fluoropropyl)sulphinic acid, (25)-(3-amino- 2-hydroxypropyl)sulphinic acid, (2R)-(3-amino-2-hydroxypropyl)sulphinic acid and (3- amino-2-oxopropyl)sulphinic acid.
Within the scope of the invention, it is to be understood that when R, is an oxo group the bond between R; and the carbon is a double bond.
Within the invention C;-C7 alkyl can be straight, branched or cyclic alkyl and is, for example, C1-C4 alkyl, such as methyl, ethyl, n-propyl! or n-butyl, also isopropyl, isobutyl, secondary butyl or tertiary butyl, but may also be a C5-C7 alkyl group such as a pentyl, hexyl or heptyl group.
C,-C5 alkoxy is, for example, C;-C4 alkoxy, such as methoxy, ethoxy, n-propoxy or n- butoxy, also isopropoxy, isobutoxy, secondary butoxy or tertiary butoxy, but may also be a
Cs5-C+ alkoxy group, such as a pentoxy, hexoxy or heptoxy group.
Cy-C5 thioalkoxy is, for example, C1-C4 thioalkoxy, such as thiomethoxy, thioethoxy, n- thiopropoxy or n-thiobutoxy, also thioisopropoxy, thioisobutoxy, secondary thiobutoxy or tertiary thiobutoxy, but may also be a Cs-C7 thioalkoxy group, such as a thiopentoxy, thiohexoxy or thioheptoxy group. .
Halogen as used herein is anyone of chlorine, fluorine, bromine or iodine.
The herein used term aryl means aromatic rings with 6-14 carbon atoms including both : single rings and polycyclic compounds, such as benzyl or naphtyl, optionally substituted with one or more substituents such as membered rings optionally substituted with one or more substituents such as Cy-C7 alkyl, C;-C7 alkoxy, halogen, C1-C7 thioalkoxy, hydroxy, 5s mercapto, carboxylic acid, carboxylic acid ester, carboxylic acid amide or nitrile.
The term heteroaryl as used herein means aromatic rings with 5-14 carbon atoms, including both single rings and polycyclic compounds, in which one or several of the ring atoms is either oxygen, nitrogen or sulphur. The heteroaryl is optionally substituted with one or more substituents such as C;-C7 alkyl, C;1-C7 alkoxy, C;-C7 thioalkoxy, halogen, hydroxy, mercapto, carboxylic acid, carboxylic acid ester, carboxylic acid amide or nitrile.
The compounds according to formula I of the invention are of amphoteric nature and may be presented in the form of internal salts. They can also form acid addition salts and salts with bases. Such salts are particularly pharmaceutically acceptable acid addition salts, as well as pharmaceutically acceptable salts formed with bases. Suitable acids for the formation of such salts include, for example, mineral acids such as hydrochloric, hydrobromic, sulfuric, or phosphoric acid or organic acids such as sulfonic acids and . carboxylic acids. Salts with bases are, for example, alkali metal salts, e.g. sodium or potassium salts, or alkaline earth metal salts, e.g. calcium or magnesium salts, as well as ammonium salts, such as those with ammonia or organic amines. The salts may be . prepared by conventional methods.
When one or more stereocentre is present in the molecule, the compounds according to 2s formula I can be in the form of a stereoisomeric mixture, i.e. a mixture of diastereomers and/or racemates, or in the form of the single stereoisomers, i.e. the single enantiomer and/or diastereomer. The compounds can also be in the form of solvates, e.g. hydrates.
The compounds according to the formula I can be used for the inhibition of TLOSR, and thus for the treatment of gastro-oesophageal reflux disease. The said inhibition of TLOSR also implies that the said compounds of formula I can be used for the treatment of regurgitation in infants. Effective management of regurgitation in infants would be an important way of managing failure to thrive due to excessive loss of ingested nutrient.
Furthermore the compounds can be used for the treatment of GORD-related or non-GORD related asthma, belching, coughing, pain, cocaine addiction, hiccups, IBS, dyspepsia, emesis and nociception.
One aspect of the invention is the use of the compounds of formula I
H R, OH
NS (1)
R 3 R 1 wherein
R; represents hydrogen, hydroxy, C;1-C7 alkyl, C1-C7 alkoxy or halogen;
Ra represents hydrogen, hydroxy, mercapto, halogen, or an oxo group;
Rs represents hydrogen or C1-C~ alkyl (optionally substituted with hydroxy, mercapto, Ci-
C7 alkoxy, C1-C7 thioalkoxy, aryl or heteroaryl), aryl or heteroaryl;
Ry represents hydrogen, C;-C~ alkyl (optionally substituted with aryl or heteroaryl), aryl or heteroaryl; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, in the \ manufacture of a medicament for the inhibition of TLOSR and thus for the treatment of gastro-oesophageal reflux disease, regurgitation in infants and also for the treatment of -
GORD-related or non-GORD related asthma, belching, coughing, pain, cocaine addiction, hiccups, IBS, dyspepsia, emesis and nociception.
Another aspect of the invention is a method for the inhibition of TLOSR, for the treatment : of gastro-oesophageal reflux disease, regurgitation in infants and also for the treatment of
GORD-related or non-GORD related asthma, hyperkinesia, belching, coughing, pain, ) cocaine addiction, alcohol withdrawal, nicotine dependence, hiccups, IBS, dyspepsia, 5s emesis and nociception, which method comprises treating a subject suffering from said condition with a pharmacuetical preparation comprising a compound of the formula I
HR OH
N S (1)
RY Ny J 0
R: RR; wherein
R; represents hydrogen, hydroxy, C;-C7 alkyl, C;-C7 alkoxy or halogen;
R; represents hydrogen, hydroxy, mercapto, halogen, or an oxo group;
Rj represents hydrogen or C1-C7 alkyl (optionally substituted with hydroxy, mercapto, C;-
C7 alkoxy, C1-C7 thioalkoxy, aryl or heteroaryl), aryl or heteroaryl; : R4 represents hydrogen, C1-C5 alkyl (optionally substituted with aryl or heteroaryl), aryl or : 20 heteroaryl; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof.
A further aspect is a pharmaceutical preparation comprising the compounds of the invention comprising as active ingredient a therapeutically acceptable amount of a . 2s compound according to formula I optionally in association with diluents, excipients or inert carriers.
The wording “TLOSR?”, transient lower oesophageal sphincter relaxations, is herein defined in accordance with Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A.,
Dent, J., 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610. -
The wording “reflux” is herein defined as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.
The wording “GORD”, gastro-oesophageal reflux disease, is herein defined in accordance with van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Bailliére’s
Clin. Gastroenterol. 14, pp. 759-774. )
The term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary. The terms “therapeutic” and “therapeutically” should be construed accordingly.
Preparation
The compounds according to formula I of the present invention may be prepared by one of the following methods.
A) A compound of formula II 2
Pv AN gor (i)
Oo
R: R, in which R; and Rj; are as defined above in formula I, Pht is a protecting group such as phtalimido and Y is hydrogen or a protecting group such as C;-C7 alkyl, which compound of formula II may have been synthesized by a condensation reaction according to Scheme 1 employing an appropriate N-protected amino acid ester in which Rs is as defined above,
W is a protecting group such as C;-C7 alkyl and Pht is as defined in formula II, and a suitable protected sulphonic acid derivative in which R; is as defined above in formula I and Y is as defined in formula II, and a base such as lithium diisopropylamide,
Oo Q 0 Q
PhtN + _§—OQy Base pnN S—OY ow r I — I 0) Oo
R 3 R 1 R 3 R 1 s Scheme 1 is a) optionally converted by a ketal formation reaction in order to protect the keto group, a hydrolytic reaction followed by a deoxohalogenation reaction in order to obtain a sulphonic acid halide, a hydrazinolysis in order to detach the N-protective group and at the same time obtain a sulphinic acid derivative, optionally an N-alkylation reaction in order to introduce Ry if Ry is desired to be not equal to hydrogen, and thereafter a hydrolytic reaction to obtain a compound of formula III :
Oo O
H [1
RN S<oH (In)
R 3 R 1 wherein R;, R; and R, are as defined above in formula I, and optionally convert the above resulting compound II into another chemical compound of the formula III and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula III and/or into another salt and/or convert a resulting } free compound of the formula III into a salt to correspond to the above definition, or b) converted by a reductive reaction in order to reduce the keto group, a hydrolytic reaction followed by a deoxohalogenation reaction in order to obtain a sulphonic acid halide, a hydrazinolysis in order to detach the N-protective group and at the same time obtain a sulphinic acid derivative, optionally an N-alkylation reaction in order to introduce Ry if R4 } 1s desired to be not equal to hydrogen, and thereafter a hydrolytic reaction to obtain a compound of formula IV
OH O
H [i
Aon (IV)
Rs. R, wherein Ry, Rj; and R, are as defined above in formula I, and optionally convert the above resulting compound IV into another chemical compound of the formula IV and/or separate a resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula IV and/or into another salt and/or convert a resulting free compound of the formula IV into a salt to correspond to the above definition, or c) converted by a reductive reaction followed by a deoxohalogenation reaction, a hydrolytic reaction followed by a deoxohalogenation reaction in order to obtain a sulphonic acid halide, a hydrazinolysis in order to detach the N-protective group and at the same time obtain a sulphinic acid derivative, optionally an N-alkylation reaction in order to introduce Ry if Ry is desired to be not equal to hydrogen, and thereafter a hydrolytic reaction to obtain a compound of formula V
Halo O
H (
R+ AN on (V)
Rs RR, 0 wherein Ry, R3 and Ry are as defined above in formula I and Halo is a halogen atom, and optionally convert the above resulting compound V into another chemical compound of the
Co formula V and/or sepatate a resulting mixture of isomers into the individual isomers and/or . convert a resulting salt into the free compound of the formula V and/or into another salt and/or convert a resulting free compound of the formula V into a salt to correspond to the . above definition; or
B) a compound of formula VI © OH N
PhEN s— (v1)
S
R; R, in which Ry, R; and Rj are as defined above in formula I, Pht is a protecting group such as phtalimido, which compound of formula VI may have been synthesized by a reaction according to Scheme 2 employing an 2,3-epoxypropyl derivative, such as an appropriate
N-protected 2,3-epoxypropylamine derivative, in which R; and Rs are as defined above in formula I and Pht is as defined above in formula VI, and 2-mercaptobenzothiazole and a base, 0 N base
P< + Hs— | :
S
Rs R;
OH N-
PhtN s— 1
S
’ R 3 R 1
Scheme 2 is a) optionally converted by a hydrazinolysis followed by an acylation reaction if the N- protective group is desired to be changed from a phtalimido group to for instance a t-Boc } group, optionally an N-alkylation reaction in order to introduce Ry if Ry is desired to be not equal to hydrogen, an oxidation reaction followed by a reduction reaction in order to obtain : asulphinic acid, and thereafter a hydrolytic reaction to obtain a compound of formula IV
OH O
H 1
R+—N So (IV) pon
R: R, wherein Ry, R3 and Ry are as defined above in formula I, and optionally convert the above resulting compound IV into another chemical compound of the formula IV and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula IV and/or into another salt and/or convert a resulting free compound of the formula TV into a salt to correspond to the above definition, or b) optionally converted by a hydrazinolysis followed by an acylation reaction if the N- protective group is desired to be changed from phtalimido group to for instance a t-Boc : group, optionally an N-alkylation reaction in order to introduce Ry if Ry is desired to be not equal to hydrogen, an oxidation reaction followed by a ketal formation reaction, an oxidation reaction followed by a reduction reaction in order to obtain a sulphinic acid, and thereafter a hydrolytic reaction to obtain a compound of formula VII
O O
H I
Rz ANS (Vin)
R; R, 2s wherein Ry, R3 and Ry are as defined above in formula I, and optionally convert the above resulting compound VII into another chemical compound of the formula VII and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert a -
resulting salt into the free compound of the formula VII and/or into another salt and/or ] convert a resulting free compound of the formula VII into a salt to correspond to the above definition, or : 5c) optionally converted by a hydrazinolysis followed by an acylation reaction if the N- protective group is desired to be changed from phtalimido group to for instance a t-Boc group, optionally an N-alkylation reaction in order to introduce Ry if R4 is desired to be not equal to hydrogen, a deoxohalogenation reaction, an oxidation reaction followed by a reduction reaction in order to obtain a sulphinic acid, and thereafter a hydrolytic reaction to obtain a compound of formula VIII
H Halo Q ell Aon (vi
Rs R, wherein Ry, R; and Ry are as defined above in formula I, and Halo is a halogen atom, and optionally convert the above resulting compound VIII into another chemical compound of the formula VIII and/or sepatate a resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula VIII and/or into another salt and/or convert a resulting free compound of the formula VIII into a salt to correspond to the above definition; or
C) a compound of formula IX
R. N
Pv As 1) (IX)
S
R: R, in which Rj, Ry and Rs are as defined above in formula I, which compound of formula IX may have been synthesized by two subsequently substitution reactions according to
Scheme 3 employing a compound in which R;, R; and Rj are as defined above in formula I,
L; and L, are leaving groups, and potassium phtalimid followed by 2- mercaptobenzothiazole and a base, i
R., .
N Base
HS >
R. R, S
R. MN Potassium R, N
L, s—( phialimide pp s—{
S B — S
R 3. R 1 R 3 R ;
Scheme 3 optionally is converted by a hydrazinolysis followed by an acylation reaction if the N- protective group is desired to be changed from phtalimido group to for instance a t-Boc group, optionally an N-alkylation reaction in order to introduce Ry if Ry is desired to be not - equal to hydrogen, an oxidation reaction followed by a reduction reaction in order to obtain a sulphinic acid, and thereafter a hydrolytic reaction to obtain a compound of formula I
R, O ‘ ov 0 wherein R; and Ry are as defined above in formula I, and optionally convert the above resulting compound I into another chemical compound of the formula I and/or separate a : resulting mixture of isomers into the individual isomers and/or convert a resulting salt into the free compound of the formula I and/or into another salt and/or convert a resulting free “compound of the formula I into a salt to correspond to the above definition.
The invention is described more in detail by the following non-limiting examples.
Example 1. (25)-(3-Amino-2-hydroxypropyl)sulphinic acid. tert-Butyl (25)-3-(1,3-benzothiazol-2-ylsulphonyl)-2-hydroxypropylcarbamate (9.30 g, 25.0 mmol) was dissolved in ethanol (100 mL) and then cooled to 0 °C. Solid sodium borohydride (1.89 g, 50.0 mmol) was added and the reaction was then warmed to rt and stirred overnight. The reaction was then re-cooled to 0 °C and was quenched by the addition of ethyl acetate/HCI (15 mL) and then allowed to stir for 1.5 h. The solvents were removed under reduced pressure and the residue was purified by ion exchange chromatography (Dowex® 50WX-8-200, H' form). The crude product was suspended in 1:1 methanol/water, loaded onto the resin column and washed with 1:1 methanol/water.
The eluent was changed to 1:1 methanol/concentrated ammonium hydroxide to remove the product. Concentration under reduced pressure of the fractions containing product afforded a solid which was triturated with methanol to afford (25)-(3-amino-2- hydroxypropyl)sulphinic acid (1.51 g, 43%) as a white solid. Data for afford (25)-(3- amino-2-hydroxypropyl)sulphinic acid: mp = 206-208 °C; APCI mass spectrum m/z = 140;
Optical Rotation [0]*p = +86.94° (c=1.0, Water); TH NMR (300 MHz, D,0) § 4.14 (m, 1H), 3.11 (dd, J=13 Hz, J=3 Hz, 1H), 2.91 (dd, J=13 Hz, J=9 Hz, 1H), 2.61 (dd, J=13 Hz,
J=9 Hz, 1H), 2.30 (dd, /=13 Hz, J=4 Hz, 1H).
Example 2. (2R)-(3-Amino-2-hydroxypropyl)sulphinic acid. tert-Butyl (2R)-3-(1,3-benzothiazol-2-ylsulphonyl)-2-hydroxypropylcarbamate (6.47 g, 17.3 mmol) was dissolved in ethanol (100 mL) and then cooled to 0 °C. Solid sodium “30 borohydride (1.70 g, 44.9 mmol) was added and the reaction was then warmed to roomtemperature and stirred overnight. The reaction was then re-cooled to 0 °C and was quenched by the addition of ethyl acetate/HCI (100 mL) and then allowed to stir for 2 h. y
The solvents were removed under reduced pressure and the residue was purified by ion exchange chromatography (Dowex® S0WX-8-200, H' form). The crude product was suspended in 1:1 methanol/water, loaded onto the resin column and washed with 1:1 methanol/water. The eluent was changed to 1:1 methanol/concentrated ammonium ’ s hydroxide to remove the product. Concentration under reduced pressure of the fractions containing product afforded a solid which was triturated with methanol to afford (2R)-(3- amino-2-hydroxypropyl)sulphinic acid (1.03 g, 43%) as a white solid. Data for (2R)-(3- amino-2-hydroxypropyl)sulphinic acid: mp = 210 °C; APCI mass spectrum m/z = 140;
Optical Rotation [0,2 © = -88.6° (c=1.00, Water); "H NMR (300 MHz, D,0) 6 4.17 (m, 1H), 3.14 (m, 1H), 2.95 (dd, J=13 Hz, J=9 Hz, 1H), 2.63 (dd, J=13 Hz, J=9 Hz, 1H), 2.33 (dd, J=13 Hz, J=4 Hz, 1H).
The following intermediates were used in the preparation of compounds of the invention.
Example 3 : 3-Amino-(2R)-2-fluoro-1-propanesulfinic acid
Carbamic acid, [(2R)-3-[(1,1-dimethylethyl}sulfonyl]-2-fluoropropyl)-, 1,1-dimethylethyl ester (5 g, 16.8 mmol) was dissolved in methylene chloride (60 mL) and cooled to 0 °C.
Neat trifluoromethanesulfonic acid (12.5 mL, 14] mmol) was added dropwise over 3 minutes to the rapidly stirred solution. After 2 h the methylene chloride is removed on a rotary evaporator, the residue is cooled to 0 °C and then water (30 mL) is added. Any precipitate formed is removed by filtration and then the solution is loaded onto a Dowex 50WX8-200 column which has been pre-washed with 1:1 methanol/water and then with just water. The column is eluted with water until all of the triflic acid is off and then the product is removed with 3:1 methanol/concentrated ammonium hydroxide. Concentration of the appropriate fractions provides crude 3-Amino-2-fluoro-(2R)-1-propanesulfinic acid. .
Purification by silica gel column chromatography eluting with(6:3:1 methylene chloride/ methanol/concentrated ammonium hydroxide provided pure title compound (782 mg, 33%) as a white solid.
Data: mp 136-138 °C, R=0.35 (methylene chloride, methanol, concentrated ammonium hydroxide (6:3:1), ninhydrin development), m/z = 140 (M-H), H NMR (300 MHz, D,0), 8 5.22 (m, 0.5H), 5.06 (m, 0.5H), 3.32 (m, 2H), 2.88 (m, 1H), 2.48 (m, 1H).
Intermediates
Example 11. tert-Butyl (25)-3-(1.3-benzothiazol-2-ylsulphonyl)-2- hydrox ypropylcarbamate. tert-Butyl (25)-3-(1 ,3-benzothiazol-2-ylthio)-2-hydrox ypropylcarbamate (33.5g,68.8 mmol, i.e. maximum theoretical amount) was dissolved in methylene chloride (750 mL) and then treated with 3-chloroperoxybenzoic acid (29.7 g, 172 mmol) in small portions.
After the reaction was stirred for 3 days, the mixture was washed sequentially witha - solution of sodium bicarbonate followed by a solution of saturated sodium chloride. The organic layer was dried with magnesium sulfate, filtered and concentrated under reduced pressure to afford crude tert-butyl (25)-3-(1,3-benzothiazol-2-ylsulphonyl)-2- hydroxypropylcarbamate. Purification on silica gel eluting with 4:1 methylene chloride/ethyl acetate gave terz-butyl (25)-3-(1,3-benzothiazol-2-ylsulphonyl)-2- hydroxypropylcarbamate (9.30 g, 36% from terr-butyl (25)-3-(1,3-benzothiazol-2-ylthio)- 2-hydroxypropylcarbamate) as a white solid. Data for tert-butyl (25)-3-(1,3-benzothiazol- 2-ylsulphony!)-2-hydroxypropylcarbamate: 'H NMR (300 MHz, CDCl) 6 8.22 (d, 1H), 8.04 (d, 1H), 7.70-7.60 (m, 2H), 5.03 (m, 1H), 4.48 (m, 1H), 4.19 (m, 1H), 3.72 (m, 2H), 3.50-3.30 (m, 2H), 1.43 (s, 9H). x :
Example 12. fert-Buty] (25)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropylcarbamate.
A suspension of N-[(25)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropyl]-phthalimide (25.5 : _ 8, 68.8 mmol) in EtOH (550 mL) was treated with hydrazine hydrate (5.3 mL, 109 mmol) and heated to 50 °C for 3 h. The reaction was cooled, filtered and the solvents were removed under reduced pressure. The crude residue was taken up in methylene chloride (250 mL) and treated with di-tert-butyl dicarbonate (22.5 g, 103 mmol) then allowed to stir overnight. The solvents were then removed under reduced pressure to give crude tert-butyl (25)-3-(1,3-benzothiazol-2-yithio)-2-hydrox ypropylcarbamate. Purification on silica gel eluting with methylene chloride to start and then switching to ethyl acetate provided terz- butyl (25)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropylcarbamate (33.5 g) as an oil ‘ which was contaminated with di-terz-butyl dicarbonate residues. This compound was used directly in the next step. Data for terz-butyl (25)-3-(1,3-benzothiazol-2-ylthio)-2- hydrox ypropylcarbamate: 'H NMR (300 MHz, CDCls) 0 7.85 (d, 1H), 7.76 (d, 1H), 7.45 (dd, 1H), 7.35 (dd, 1H), 5.35 (m, 1H), 5.05 (m, 1H), 4.15 (m, 1H), 3.57-3.40 (m, 3H), 3.35- 3.25 (m, 1H), 1.48 (s, 9H).
Example I3. N-[(25)-3-(1.3-Benzothiazol-2-ylthio)-2-hydroxypropyll-phthalimide.
A suspension of N-[(25)-oxiran-2-ylmethyl]-phthalimide (18.4 g, 90.6 mmol) and 2- mercaptobenzothiazole (15.8 g, 94.5 mmol) in EtOH (530 mL) was heated to reflux for is 14.5 h. The reaction was then cooled and concentrated under reduced pressure. The crude mixture was crystallized from ethanol and filtered to provide N-[(25)-3-(1,3-benzothiazol- 2-ylthio)-2-hydroxypropyl]-phthalimide (25.5 g, 76%) as a solid. Data for N-[(25)-3-(1,3- benzothiazol-2-ylthio)-2-hydroxypropyl]-phthalimide: "H NMR (300 MHz, CDCl) $7.88 - (m, 2H), 7.75 (m, 4H), 7.45-7.26 (m, 2H), 5.15 (m, 1H), 4.42 (m, 1H), 4.08-3.88 (m, 2H), 2 3.61 (m, 1H), 3.42 (m, 1H).
Example 14. N-[(25)-Oxiran-2-ylmethyl]-phthalimide.
Triphenylphosphine (77.0 g, 294 mmol) and phthalimide (44.2 g, 300 mmol) were combined in THF (330 mL) and cooled to 0 °C. A solution of diethyl azodicarboxylate (52.2 g, 300 mmol) and (S)-(-)-glycidol (24.3 g, 328 mmol) in THF (110 mL) was added dropwise to the reaction flask. Once the addition was complete, the reaction was allowed to . warm to rt while stirring overnight. The solvents were removed under reduced pressure and the residue was stirred in diethyl ether (1 L) for 1 h. The solids were removed by filtration : and the filtrate was concentrated under reduced pressure to give crude N-[(25)-oxiran-2- ylmethyl]-phthalimide. The crude product was purified by crystallization from ethanol to provide N-[(2S)-oxiran-2-ylmethyl]-phthalimide (18.4 g, 30 %) as a white solid. Data for
N-[(2S)-oxiran-2-ylmethyl]-phthalimide: Chiral HPLC: 97% ee (Daicel ChiralPak AD column); "H NMR (300 MHz, CDCls) 8 7.88 (m, 2H), 7.76 (m, 2H), 3.97 (dd, 1H), 3.83 (dd, 1H), 3.27 (m, 1H), 2.82 (m, 1H), 2.71 (m, 1H). 5s Example I5. ter-Butyl (2R)-3-(1,3-benzothiazol-2-ylsulphonyl)-2- hydroxypropylcarbamate. tert-Butyl (2R)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropylcarbamate (18.0 g, 52.8 mmol) was dissolved in methylene chloride (700 mL) and then treated with 3- chloroperoxybenzoic acid (22.8 g, 132 mmol) in small portions. After the reaction was stirred for 3 days, the mixture was washed sequentially with a solution of sodium bicarbonate followed by a solution of saturated sodium chloride. The organic layer was dried with magnesiem sulphate, filtered and concéntrated under reduced pressure to afford crude tert-butyl (2R)-3-(1,3-benzothiazol-2-ylsulphonyl)-2-hydroxypropylcarbamate.
Purification on silica gel eluting with 4:1 methylene chloride/ethyl acetate gave zerz-butyl (2R)-3-(1,3-benzothiazo}-2-ylsulphonyl)-2-hydroxypropylcarbamate (6.47 g,33%) as a white solid. Data for tert-butyl (2R)-3-(1,3-benzothiazol-2-ylsulphonyl)-2- hydroxypropylcarbamate: 'H NMR (300 MHz, CDCls) § 8.22 (d, 1H), 8.04 (d, 1H), 7.70- 7.60 (m, 2H), 5.03 (m, 1H), 4.48 (m, 1H), 4.19 (m, 1H), 3.72 (m, 2H), 3.51-3.30 (m, 2H), 1.43 (s, 9H).
Example I6. terr-Butyl (2R)-3-(1.3-benzothiazol-2-ylthio)-2-hydroxypropylcarbamate.
A suspension of N-[(2R)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropyl]-phthalimide : (22.5 g, 60.7 mmol) in EtOH (500 mL) was treated with hydrazine hydrate (4.0 mL, 82.4 mmol) and heated to 50 °C for 4 h. The reaction was cooled, filtered and the solvents were removed under reduced pressure. The crude residue was taken up in methylene chloride (500 mL) and treated with di-terz-butyl dicarbonate (19.9 g, 91.1 mmol) then allowed to . stir overnight. The solvents were then removed under reduced pressure to give crude compound 2. Purification on silica gel eluting with methylene chloride to start and then switching to ethyl acetate provided tert-butyl (2R)-3-(1,3-benzothiazol-2-ylthio)-2- hydroxypropylcarbamate (18.0 g, 87%) as an oil. Data for tert-butyl (2R)-3-(1,3-
benzothiazol-2-ylthio)-2-hydroxypropylcarbamate: 'H NMR (300 MHz, CDCl3) 8 7.80 (d, 1H), 7.71 (d, 1H), 7.40 (dd, 1H), 7.30 (dd, 1H), 5.35 (m, 1H), 5.00 (m, 1H), 4.10 (m, 1H), 3.52-3.35 (m, 3H), 3.30-3.20 (m, 1H), 1.45 (s, 9H).
Example I7. N-[(2R)-3-( 1.3-Benzothiazol-2-ylthio)-2-hydrox ypropyll-phthalimide.
A suspension of compound N-[(2R)-oxiran-2-ylmethyl]-phthalimide (21.1 g, 104 mmol) and 2-mercaptobenzothiazole (17.4 g, 104 mmol) in EtOH (600 mL) was heated to reflux for 16.5 h. The reaction was then cooled and concentrated under reduced pressure. The crude mixture was crystallized from ethanol and filtered to provide N-{(2R)-3-(1,3- benzothiazol-2-ylthio)-2-hydroxypropyl]-phthalimide (22.5 g, 59%) as a yellow solid. Data for N-[(2R)-3-(1,3-benzothiazol-2-ylthio)-2-hydrox ypropyl]-phthalimide: ‘H NMR (300
MHz, CDCl3) 67.88 (m, 2H), 7.75 (m, 4H), 7.45-7.26 (m, 2H), 5.18 (m, 1H), 4.42 (m, 1H), 4.08-3.88 (m, 2H), 3.61 (m, 1H), 3.42 (m, 1H).
Example I8. N-[(2R)-Oxiran-2-ylmethyl]-phthalimide.
Triphenylphosphine (49.5 g, 189 mmol) and phthalimide (28.4 g, 193 mmol) were combined in THF (220 mL) and cooled to 0 °C. A solution of diethyl azodicarboxylate (33.6 g, 193 mmol) and (R)-~(+)-glycidol (16.4 g, 222 mmol) in THF (75 mL) was added dropwise to the reaction flask. Once the addition was complete, the reaction was allowed to warm to rt while stirring overnight. The solvents were removed under reduced pressure and the residue was stirred in diethyl ether (750 mL) for 1 h. The solids were removed by filtration and the filtrate was concentrated under reduced pressure to give crude N-[(2R)- oxiran-2-ylmethyl}-phthalimide. The crude product was purified by silica gel chromatography using 1:1 heptane/ethyl acetate to provide compound N-[(2R)-oxiran-2- ylmethyl]-phthalimide (19.1 g, 50 %) as a white solid. Data for N-[(2R)-oxiran-2- ylmethyl}-phthalimide: '"H NMR (300 MHz, CDCls) 6 7.88 (m, 2H), 7.76 (m, 2H), 3.97 (dd, 1H), 3.83 (dd, 1H), 3.27 (m, 1H), 2.82 (m, 1H), 2.71 (m, 1H). :
LL
Example 19
Carbamic acid, [(2R)-2-fluoro-3-[(methylsulfonyl Joxylpropyll-, 1.1-dimethylethyl ester (intermediate 1 to the compound according to Example 4) . Carbamic acid, [(2R)-2-fluoro-3-hydroxypropyl]}-, 1,1-dimethylethyl ester 1627 g (8.43 5s mol) was dissolved in THF (7100 mL) and treated with triethylamine (1117 g, 11 mol) and the resulting mixture was cooled to 0-5 °C. Methanesulfonylchloride (940 g, 8.21 mol) was introduced dropwise at such a rate that the temperature was maintained at 0-5 °C.
After 30 minutes additional triethylamine (225 g, 2.22 mol) and methanesuifonyl chloride (185 g, 1.62 mol) were added. After 2 hours the mixture was quenched by the addition of water (8000 mL) while keeping the temperature below 10 °C, extracted with tert-butyl methyl ether (8000 mL) and the organic phase was separated. The solution was washed with water (5000 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to a residue that became a slurry as the concentration neared completion. The slurry was then treated with hexane (3000 mL), cooled to 0-5 °C, filtered and the solids were washed with hexane (1000 mL). The filtrate was concentrated to a residue and a second crop of product was isolated by crystallization from the hexane solutions. The two crops were analyzed to show that they were pure product samples and thus were combined and dried in a vacuum oven at 40-50 °C to provide a white crystalline solid (1240 g, 53%).
Data: '"H NMR (300 MHz, CDCl) 64.89 (m, 1.5H), 4.74 (m, 0.5H), 4.43 (m, 1H), 4.36 (m, 1H), 3.50 (m, 1H), 3.43 (m, 1H), 3.08 (s, 3H), 1.45 (s, 9H).
Example I 10
Carbamic acid, [(2R)-3-[(1.1-dimethylethyl)thio]-2-fluoropropyl]-, 1,1-dimethylethy! ester (intermediate 2 to the compound according to Example 4)
Carbamic acid, [(2R)-2-fluoro-3-[(methylsulfonyl)oxylpropyll-, 1,1-dimethylethyl ester (13.0 g, 47.9 mmol), 2-methyl-2-propanethiol (5.39 mL, 47.8 mmol) and cesium carbonate (23.4 g, 71.8 mmol) were combined in acetonitrile (300 mL) and heated to reflux for 3.5 h.
The crude reaction mixture was filtered to remove solids and the filtrate was concentrated under reduced pressure. Purification by silica gel column chromatography eluting with 90:10 methylene chloride/ethyl acetate afforded carbamic acid, [(2R)-3-[(1,1- dimethylethyl)thio]-2-fluoropropyi]-, 1,1-dimethylethyl ester as an oil (11.1 g, 87%).
Data: 'H NMR (300 MHz, CDCl3) 6 4.87 (br s, 1H), 4.72 (m, 0.5H), 4.58 (m, 0.5H), 3.59 (m, 1H), 3.30 (m, 1H), 2.78 (m, 2H), 1.32 (s, 9H), 1.45 (s, 9H).
Example 111
Carbamic acid, [(2R)-3-{(1,1-dimethylethyl)sulfonyl]-2-fluoropropyll-, 1,1-dimethylethyl ester (intermediate 3 to the compound according to Example 4)
Carbamic acid, [(2R)-3-[(1,1-dimethylethyl)thio]-2-fluoropropyl]-, 1,1-dimethylethyl ester (11.1 g, 41.9 mmol) was dissolved in methylene chloride (300 mL) and cooled in an ice water bath. 3-Chloroperoxybenzoic acid (23.3 g, 77%, 0.10 mol) was added portionwise then the mixture was allowed to warm to room temperature. After 2 hours dilute potassium carbonate solution was added and the reaction mixture was extracted with methylene chloride, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford crude carbamic acid, [(2R)-3-{(1,1-dimethylethyl)sulfonyl}-2- fluoropropyl]-, 1,1-dimethylethyl ester. Purification by silica gel column chromatography eluting with 90:10 methylene chloride/ethyl acetate afforded compound the title compound as a white solid (8.12 g, 65%).
L
Data: '"H NMR (300 MHz, CDCl3) § 5.28 (m, 0.5H), 5.12 (m, 0.5H), 4.98 (br s, 1H), 3.65- 3.27 (m, 4H), 1.48 (s, 9H), 1.46 (s, 9H). . Pharmaceutical preparations .
The compound according to formula I of the present invention can be used as an active ingredient in a pharmaceutical preparation for oral, rectal, epidural, intravenous, intramuscular, subcutanous, nasal administration and administration by infusion or for any other suitable route of administration. Preferably the way of administration is oral or by injection/infusion.
The pharmaceutical preparations contain a compound of the present invention in combination with one or more pharmaceutically acceptable ingredients. The finished dosage forms are manufactured by known pharmaceutical processes. Usually the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and preferably between 1-50% by weight in preparations for oral administration.
In the preparation of pharmaceutical preparations containing a compound of the present invention in the form of solid dosage units for oral administration, the compound selected may be mixed with solid pharmaceutically acceptable “ingredients (among these for instance disintegrating agents and lubricating agents). The mixture is then processed into granules, tablets, capsules or sachets. 2s Dosage units for rectal administration may be prepared in the form of suppositories; in the form of a gelatine rectal capsule; in the form of a ready-made micro enema; or in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, or in the form of a dry mixture to be reconstituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a compound of the } invention in a pharmaceutically acceptable solvent and are dispensed into ampoules or vials. They may also be prepared as a dry preparation to by reconstituted with a suitable . solvent extemporaneously before use.
The typical daily dose of the active compound will depend on various factors such as for example the individal requirement of each patient, the route of administration and the disease. In general, dosages will be in the range of from 1 pug to 100 mg per day and kg body weight. A further aspect of the invention is to administer the active compound in a dose of from 10 pg to 20 mg per day and kg body weight. The active ingredient may in one embodiment be administered once daily. In another embodiment it may administered several times daily. In yet another embodiment it may administered less often than once daily.
Biological studies [PH]GABA radioligand binding assay
Rat synaptic membranes were prepared from the whole brain of Sprague Dawley male rats essentially as described previously (Zukin, et al. (1974) Proc. Natl. Acad. USA 71, 4802- 4807). The [P'H]JGABA competition assay, modified from Olpe et al ((1990) Eur. J.
Pharmacol. 187, 27-38), was performed in 200 ul TCI (Tris Calcium Isoguvacine) buffer (50 mM Tris (tri(hydroxymethyl)aminomethane), pH 7.4, 2.5 mM CaCl, and 40 uM isoguvacine) containing 20 nM [*H]GABA (specific activity: 3 Tera Becquerel (TBq)/mmol), test compound or solvent and 80 pg synaptic membrane protein using 96- well plates. After incubation for 12-20 min at room temperature, incubations were terminated by rapid filtration through a glass fiber filter (Printed filtermat B filters,
Wallac), which had been pretreated with 0.3% polyethyleneimine, using a 96-well plate cell harvester (Skatron or Tomtec). The filters were washed with buffer containing 50 mM
Tris (tris(hydroxymethyl)aminomethane) and 2.5 mM CaCl,, pH 7.4, at 4 °C and then dried at 55° C. MeltiLex B/HS scintillator sheet (Wallac) was melted onto the filter, and . radioactivity was determined in a Microbeta scintillation counter (Wallac).
Results and discussion
The compounds of the present invention were found to have high affinities and potencies for the GABAg receptor as revealed by low ICs and ECs in the binding and ileum assays, respectively. The compounds have also been found to reduce TLOSR when administered i.v. as well as p.o. in animal models. Moreover, CNS side-effects (as measured by reduction in body temperature in the mouse) were not observable or only seen at high doses. Therefore, the difference between therapeutic dose (inhibition of TLOSR in the dog model) and dose causing side-effects (in the mouse model) was unexpectedly high.
Claims (1)
- @ * CLAIMS1. A compound according to formula IH R. oH Rs: R, wherein Rj represents hydrogen; Ry represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid.2. A compound according to claim 1 which is (3-amino-2-fluoropropyl)sulphinic acid.3. A compound according to claim 2 which is (25)-(3-amino-2-fluoropropyl)sulphinic acid.4. A compound according to claim 2 which is (2R)-(3-amino-2-fluoropropyl)sulphinic acid.5. A compound according to claim 1 which is (25)-(3-amino-2-hydroxypropyl)sulphinic . acid. . 6. A compound according to claim 1 which is (2R)—(3-amino-2-hydroxypropyl)sulphinic acid.7. A compound according to claim 1 which is (3-amino-2-oxopropyl)sulphinic acid.8. - A compound according to any one of claims 1-7, for use in therapy.:9. Use of a compound according to formula IA R. OH N S (1) Ry Ny So } R 3 R 1 . wherein R, represents hydrogen; Rj represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; R4 represents hydrogen; ) 25 and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, for the manufacture of a medicament for the inhibition of transient lower oesophageal sphincter relaxations.10. Use of a compund according to formula IH R. OH . N S (1h) ~~ NSR. ~0 Rs R, wherein R; represents hydrogen; Rp represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, for the manufacture of a medicament for the treatment of gastro-oesophageal reflux disease.11. Use of a compound according to formula I :H R. OH N S (1) rd SN Ra ~0 Rs R, : wherein Rj represents hydrogen;R, represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; 5s Ry4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, for the manufacture of a medicament for the treatment of regurgitation in infants.12. Use of a compound according to formula IH R. oH N S (n ~~ ~ R; AN ~o Rs R, wherein R; represents hydrogen; R; represents hydroxy, fluoro or an oxo group; Rs represents hydrogen; R, represents hydrogen; ) 25 and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, for the manufacture of a medicament for the treatment of GORD-related or non-GORD related asthma, hyperkinesia, belching, coughing, pain, cocaine addiction, alcohol withdrawal, nicotine dependence, hiccups, IBS, dyspepsia, emesis or nociception.13. A method for the inhibition of transient lower oesophageal sphincter relaxations whereby a therapeutically effective amount of a compound according to formula IH R. OH N S (1) 7 > R: AN pe Rs R, ~ wherein Rj represents hydrogen; R; represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; Ry represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, is administered to a subject a subject in need of such inhibition, optionally together with a pharmaceutically acceptable carrier.14. A method for the treatment of gastro-oesophaegeal reflux disease whereby a therapeutically effective amount of a compound according to formula I ’H R. oH N S (1) ~~ ~~ R’ Ny So Rs R,R4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, is administered to a subject suffering from said condition, optionally together with a . 5s pharmaceutically acceptable carrier.16. A method for the treatment of GORD-related or non-GORD related asthma, ~ hyperkinesia, belching, coughing, pain, cocaine addiction, alcohol withdrawal, nicotine dependence, hiccups, IBS, dyspepsia, emesis or nociception whereby a therapeutically effective amount of a compound according to formula IH R. oH Rs; R, wherein R; represents hydrogen; R» represents hydroxy, fluoro or an oxo group; Rj represents hydrogen; R4 represents hydrogen; 2s and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, is : administered to a subject suffering from said condition, optionally together with a pharmaceutically acceptable carrier.17. A pharmaceutical formulation comprising as active ingredient a therapeutically acceptable amount of a compound according to formula I of claim 1, together with at least one pharmacologically and pharmaceutically acceptable carrier.s 18. A compound selected from the group consiting of tert-Butyl (25)-3-(1,3-benzothiazol- 2-ylsulphonyl)-2-hydroxypropylcarbamate, tert-Butyl (25)-3-(1,3-benzothiazol-2-ylthio)- . 2-hydroxypropylcarbamate, N-[(2S)-3-(1,3-Benzothiazol-2-ylthio)-2-hydroxypropyl]- phthalimide, N-[(2S)-Oxiran-2-ylmethyl]-phthalimide, zert-Butyl (2R)-3-(1,3-benzothiazol- 2-ylsulphonyl)-2-hydroxypropylcarbamate, tert-Butyl (2R)-3-(1,3-benzothiazol-2-ylthio)-2-hydroxypropylcarbamate, N-[(2R)-3-(1,3-Benzothiazol-2-ylthio)-2-hydroxypropyl]- phthalimide, and N-[(2R)-Oxiran-2-ylmethyl]-phthalimide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102056A SE0102056D0 (en) | 2001-06-08 | 2001-06-08 | New Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200309384B true ZA200309384B (en) | 2005-03-02 |
Family
ID=20284431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200309384A ZA200309384B (en) | 2001-06-08 | 2003-12-02 | New compounds useful in reflux disease. |
Country Status (2)
Country | Link |
---|---|
SE (1) | SE0102056D0 (en) |
ZA (1) | ZA200309384B (en) |
-
2001
- 2001-06-08 SE SE0102056A patent/SE0102056D0/en unknown
-
2003
- 2003-12-02 ZA ZA200309384A patent/ZA200309384B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE0102056D0 (en) | 2001-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7034176B2 (en) | Aminopropylphosphinic acids | |
WO2002100871A1 (en) | New compounds useful in reflux disease | |
JPS649985B2 (en) | ||
RU2267495C2 (en) | New (aminopropyl)methylphosphinic acids | |
US6919379B2 (en) | Compounds useful in reflux disease | |
AU2002309420A1 (en) | New compounds useful in reflux disease | |
WO2002100869A1 (en) | New napsylate salts i | |
ZA200309384B (en) | New compounds useful in reflux disease. | |
WO2002100870A1 (en) | New napsylate salts ii | |
JPS632542B2 (en) |